What did we learn from the OPTIMAAL trial? What can we expect from VALIANT?
- 31 May 2003
- journal article
- editorial
- Published by Elsevier in American Heart Journal
- Vol. 145 (5) , 754-757
- https://doi.org/10.1016/s0002-8703(03)00168-6
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failureJournal of the American College of Cardiology, 2002
- A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart FailureNew England Journal of Medicine, 2001
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2001
- Candesartan in heart failure—assessment of reduction in mortality and morbidity (CHARM): Rationale and designJournal of Cardiac Failure, 1999
- Indications for ACE Inhibitors in the Early Treatment of Acute Myocardial InfarctionCirculation, 1998
- ACE Inhibitors in Acute Myocardial InfarctionCirculation, 1998
- Inhibition of the renin-angiotensin system after acute myocardial infarction treat first, select later?Heart, 1996
- A Clinical Trial of the Angiotensin-Converting–Enzyme Inhibitor Trandolapril in Patients with Left Ventricular Dysfunction after Myocardial InfarctionNew England Journal of Medicine, 1995
- ACE Inhibitor Use in Patients With Myocardial InfarctionCirculation, 1995
- Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure.Circulation, 1993